The global ovarian cancer drugs market is estimated to be valued at US$ 3.59 Bn in 2023 and is expected to exhibit a CAGR of 6.6% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Ovarian cancer drugs are used for treatment of ovarian cancer. Ovarian cancer starts in the ovaries, which are two small organs located on either side of the uterus that produce eggs. The majority of ovarian cancer drugs are used for treatment of ovarian epithelial cancer, which accounts for over 90% of ovarian cancer cases. Common ovarian cancer drugs include PARP inhibitors, angiogenesis inhibitors, immunotherapy drugs and chemotherapy drugs.
Market key trends:
One of the major trends in the ovarian cancer drugs market is growing adoption of immuno-oncology drugs. Immuno-oncology is an approach to treat cancer by strengthening the body's natural defenses to fight the cancer. Immune checkpoint inhibitors are a type of immunotherapy drug that work by removing inhibitors of the immune system called "checkpoints" and help immune cells to better find and attack cancer cells. Drugs such as nivolumab, pembrolizumab and others have shown promising results for treatment of ovarian cancer. Their selective targeting of cancer cells helps improve treatment outcomes with lesser side effects experienced. This has driven increasing adoption of immuno-oncology drugs for ovarian cancer globally.
Segment Analysis
The global ovarian cancer drugs market is segmented on the basis of type, application, end-user and region. Based on type, the market is segmented into alkylating agents, mitotic inhibitors, antirespiratory drugs, PARP inhibitors, immunotherapy drugs and others. Among these, PARP inhibitors dominate the market due to their high efficacy in treating BRCA gene mutation-associated ovarian cancers. PARP inhibitors help in blocking DNA repair pathways and sensitizing cancer cells to chemotherapy or radiation therapy.
Key Takeaways
The global ovarian cancer drugs market is expected to witness high growth, exhibiting CAGR of 6.6% over the forecast period, due to increasing prevalence of ovarian cancer worldwide. North America dominates the global ovarian cancer drugs market owing to high awareness regarding ovarian cancer diagnosis and treatment coupled with new product launches. Europe holds the second largest revenue share in the ovarian cancer drugs market.
Regional analysis
North America represents the largest regional market for ovarian cancer drugs accounting for over 40% of the global market share. This supremacy is majorly attributed to high healthcare expenditure, growing awareness on ovarian cancer diagnosis and treatment, new product launches, and strong presence of key market players in the region. Europe also holds significant market share.
Key players
Key players operating in the ovarian cancer drugs market are AbbVie Inc., Pfizer, Inc., AstraZeneca, F. Hoffmann-La Roche AG, Johnson & Johnson Services, Inc., Boehringer Ingelheim International GmbH, Clovis Oncology, ImmunoGen, Inc., and Vivesto AB. These companies account for majority of market share owing to their diverse product portfolio and global footprint.
No comments:
Post a Comment